E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 6/27/2017 in the Prospect News Liability Management Daily.

Italy’s Kedrion tenders for €300 million of 4.625% notes due 2019

By Susanna Moon

Chicago, June 27 – Kedrion SpA began a cash tender offer for its €300 million of 4.625% notes due April 24, 2019.

The purchase price will be 107% of par, or €1,070 per €1,000 principal amount, plus accrued interest to but excluding the settlement date.

The tender offer will continue until 11 a.m. ET on July 4.

The offer contains a new notes condition.

Kedrion is making the offer “to optimize its financial structure, including debt maturities and cost of debt,” according to a company announcement.

The company said it plans to issue a series of new euro-denominated notes, which would allow an extension of the average maturity of its debt and to reduce the average cost based on interest rates in the Eurozone.

Tender instructions must be submitted for a minimum of €100,000 principal amount and in integrals of €1,000 after that.

Settlement has been set for July 12.

The joint dealer managers are Banca IMI SpA (+39 02 72615938 or Liability.Management@bancaimi.com), Mediobanca - Banca di Credito Finanziario SpA (+39 02 88291 or MB_LM _CORP_IT@mediobanca.com) and Natixis (+390200667154 or liability.management-corporate@natixis.com).

The tender agent is Lucid Issuer Services Ltd. (+44 0 20 7704 0880 or kedrion@lucid-is.com).

Kedrion is a global biopharmaceutical company located in Lucca, Italy.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.